8-(3-(<em>R</em>)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes
Matthias Eckhardt(University of Bonn), Frank Himmelsbach(Boehringer Ingelheim (Germany)), Moh Tadayyon(Boehringer Ingelheim (Germany)), Peter Sieger(Boehringer Ingelheim (Germany)), Herbert Nar(Boehringer Ingelheim (Germany)), Ralf Lotz(Boehringer Ingelheim (Germany)), LEO THOMAS, Brian D. Guth(Boehringer Ingelheim (Germany)), Waldemar Pfrengle, Elke Langkopf(Boehringer Ingelheim (Germany)), Michael Mark, Holger Fuchs(Boehringer Ingelheim (Germany))
DORA PSI (Paul Scherrer Institute)
January 1, 2007
Cited by 0
Related Papers
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383
Adult Ceramide Synthase 2 (CERS2)-deficient Mice Exhibit Myelin Sheath Defects, Cerebellar Degeneration, and Hepatocarcinomas
|Journal of Biological Chemistry|2009|303